Xcout Intel
OncoHost
OncoHost is an Israeli precision-oncology biotechnology company that develops blood-based proteomic tests and computational analytics to characterize cancer patients and predict responses to immunotherapy. Its products are intended to help oncologists personalize treatment decisions and identify mechanisms of resistance, serving cancer patients, clinicians, pharmaceutical companies, and researchers.
Subscribe to see OncoHost’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
OncoHost at a glance
OncoHost is a biotech company headquartered in Israel, founded in 2017. Xcout tracks 8 named people at OncoHost, including Ofer Sharon (CEO).
OncoHost leadership
- Ofer SharonCEO
- Moti HachamCFO
- Yehonatan ElonCTO
- Adam DickerChief Medical Officer
- Chris DingmanCCO
- Yuval ShakedCo-Founder & Chief Scientific Advisor
2 more named people on record for OncoHost, with roles, board committees and tenure — see the full roster →
OncoHost competitors
A few of OncoHost's closest competitors — see the full list of competitors and alternatives →
Impact Proteomics provides a proprietary antigen profiling and protein identification platform that analyzes patient samples to map disease-associated antigens without cloned intermediates. The company serves biotechnology and diagnostic partners by enabling target discovery, companion diagnostics development, and therapeutic selection for oncology and autoimmune diseases.
Orchestra Health Technologies provides a platform combining proprietary software and care navigators to streamline the oncology diagnostic journey from biopsy to treatment decisions. The company serves cancer patients, oncologists, pathologists, and healthcare executives by coordinating pathology, molecular testing, and multi-disciplinary team workflows to accelerate precision medicine.
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
Nucleix is a liquid biopsy company headquartered in Rehovot, Israel. It aims to revolutionize cancer treatment through earlier disease detection, focusing on interventions that can bring the greatest impact.
Predicta Biosciences is a precision oncology company that builds a molecular insights platform for blood cancer care. By utilizing a single blood sample, the company integrates multiomics and liquid biopsies to generate longitudinal genomic and immune insights for diagnostics.
Olink Proteomics provides high-throughput protein biomarker analysis products, instruments, software, and analysis services for life science research and drug development. Utilizing its proprietary Proximity Extension Assay (PEA) technology and next-generation sequencing, the company serves researchers and pharmaceutical organizations focused on biomarker discovery and precision medicine.
Get OncoHost's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on OncoHost in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access